InspireMD, Inc. (NSPR)
| Market Cap | 54.42M -27.8% |
| Revenue (ttm) | 10.85M +54.4% |
| Net Income | -51.31M |
| EPS | -0.71 |
| Shares Out | 48.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,885 |
| Open | 1.130 |
| Previous Close | 1.140 |
| Day's Range | 1.130 - 1.140 |
| 52-Week Range | 1.020 - 2.932 |
| Beta | 0.82 |
| Analysts | Buy |
| Price Target | 3.00 (+165.49%) |
| Earnings Date | May 4, 2026 |
About NSPR
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection syste... [Read more]
Financial Performance
In 2025, InspireMD's revenue was $8.98 million, an increase of 28.11% compared to the previous year's $7.01 million. Losses were -$48.79 million, 52.4% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for NSPR stock is "Buy" and the 12-month stock price target is $3.0.
News
InspireMD Transcript: Bank of America Global Healthcare Conference 2026
Stroke prevention is shifting rapidly toward endovascular stenting, driven by strong clinical evidence and expanded coverage. The flagship stent demonstrates best-in-class outcomes and is now being commercialized in the U.S., with significant market growth expected.
InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference
MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced...
InspireMD price target lowered to $3 from $4 at Piper Sandler
Piper Sandler analyst Adam Maeder lowered the firm’s price target on InspireMD (NSPR) to $3 from $4 and keeps an Overweight rating on the shares. The firm notes the company…
InspireMD reports Q1 EPS (16c), consensus (18c)
Reports Q1 revenue $3.4M, consensus $2.7M. “Our first quarter results reflect strong underlying demand and consistent clinical outcomes for our CGuard carotid stent implant both in the U.S. and intern...
InspireMD Earnings Call Transcript: Q1 2026
Q1 2026 revenue surged 122% year-over-year to $3.4M, driven by strong global demand, but U.S. commercialization paused due to technical issues with the CGuard Prime 135 delivery system. Full-year guidance was withdrawn, with FDA approval for relaunch targeted for Q3 2026.
InspireMD Reports First Quarter 2026 Financial Results
- Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro pr...
InspireMD price target lowered to $4 from $5 at Lake Street
Lake Street lowered the firm’s price target on InspireMD (NSPR) to $4 from $5 and keeps a Buy rating on the shares. InspireMD’s voluntary recall of the CGuard Prime 135…
InspireMD withdrawing prior FY26 revenue guidance
InspireMD (NSPR) announced that, in consultation with the U.S. Food and Drug Administration, the company has initiated a voluntary recall in the U.S. for its CGuard Prime 135 cm carotid…
InspireMD initiates voluntary U.S. recall of CGuard Prime 135 cm system
InspireMD (NSPR) announced that, in consultation with the U.S. Food and Drug Administration, the company has initiated a voluntary recall in the U.S. for its CGuard Prime 135 cm carotid…
InspireMD announces FDA approval of IDE application for CGUARDIANS III study
InspireMD (NSPR) announced that the U.S. FDA has approved the company’s Investigational Device Exemption Application to initiate the CGUARDIANS III pivotal study of its SwitchGuard neuro protection sy...
InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System
- Strong clinical demand continues in Q1 2026 with global year-over-year unit sales growth of 53% and quarter-over-quarter U.S. unit sales growth of 34% -
InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System
MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced...
InspireMD to Announce First Quarter 2026 Financial Results
MIAMI, April 27, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fir...
InspireMD Transcript: 25th Annual Needham Virtual Healthcare Conference
A novel carotid stent with MicroNet mesh is driving a shift from surgery to stenting, supported by strong clinical outcomes, CMS reimbursement changes, and a robust commercial strategy. Financially, the company is well-capitalized through 2027, with plans for further expansion and new product launches.
InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference
MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upco...
InspireMD Earnings Call Transcript: Q4 2025
Q4 2025 revenue grew 62% year-over-year to $3.1M, driven by U.S. CGuard Prime launch and international growth. 2026 revenue is projected at $13–$15M, with acceleration expected in H2 from new indications and enhanced delivery systems.
InspireMD reports Q4 EPS (14c), consensus (19c)
Reports Q4 revenue $3.1M, consensus $2.63M. “We continue to see robust early momentum in our U.S. business with CGuard Prime and growing demand internationally for CGuard as we build a…
InspireMD sees FY26 revenue $13M-$15M, consensus $14.55M
The Company is providing its initial expectations for full year 2026. Management currently expects revenue for the full year 2026 to be in the range of $13 million to $15…
InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results
MIAMI, March 18, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announc...
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results
MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fou...
InspireMD participates in a conference call with Lake Street
Conference call with management will be held on February 20 hosted by Lake Street.
InspireMD initiated with a Buy at Maxim
Maxim initiated coverage of InspireMD (NSPR) with a Buy rating and $6 price target
InspireMD reports inducement grants under Nasdaq listing rule
InspireM announced that the Compensation Committee of InspireMD’s (NSPR) Board of Directors approved inducement grants to one new non-executive employee in the aggregate amount of 36,118 shares of res...
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announce...
InspireMD announces publication of C-GUARDIANS trial
InspireMD (NSPR) announced that results from the Company’s C-GUARDIANS trial have now been published in the Journal of the American College of Cardiology. The data demonstrate the safety and efficacy…